Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Amgen announces an $840 million acquisition of Dark Blue Therapeutics, GSK enters a multi-year precision medicine collaboration with Helix, and industry leaders examine how workable operating models are reshaping cell and gene therapy commercialization.

Amgen has agreed to acquire Dark Blue Therapeutics in an $840 million transaction, strengthening its pipeline in targeted small-molecule therapies. The acquisition reflects Amgen’s continued focus on external innovation to bolster its late-stage and mid-stage development portfolio.

GSK has entered a multi-year collaboration with Helix aimed at advancing precision medicines using large-scale genomic and clinical data. The partnership is designed to improve target identification and accelerate development of therapies tailored to specific patient populations.

In commercialization strategy news, a new analysis highlights the need for more workable operating models in cell and gene therapy. As CGT products move beyond early launches, manufacturers are rethinking organizational design, health system engagement, and cross-functional coordination to support sustainable commercial growth.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.